FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2908006499> ?p ?o ?g. }

• W2908006499 abstract "The GTPase KRas4B has been utilized as a principal target in the development of anticancer drugs. PDE6δ transports KRas4B to the plasma membrane, where it is released to activate various signaling pathways required for the initiation and maintenance of cancer. Therefore, identifying new small molecules that prevent activation of this GTPase by stabilizing the KRas4B-PDE6δ molecular complex is a practical strategy to fight against cancer. The crystal structure of the KRas4B-PDE6δ heterodimer was employed to locate possible specific binding sites at the protein-protein interface region. Virtual screening of Enamine-database compounds was performed on the located potential binding sites to identify ligands able to simultaneously bind to the KRas4B-PDE6δ heterodimer. A molecular dynamics approach was used to estimate the binding free-energy of the complex. Cell viability and apoptosis were measured by flow cytometry. G-LISA was used to measure Ras inactivation. Western blot was used to measure AKT and ERK activation. MIA PaCa-2 cells implanted subcutaneously into nude mice were treated with D14 or C22 and tumor volumes were recorded. According to the binding affinity estimation, D14 and C22 stabilized the protein-protein interaction in the KRas4B-PDE6δ complex based on in vitro evaluation of the 38 compounds showing antineoplastic activity against pancreatic MIA PaCa-2 cancer cells. In this work, we further investigated the antineoplastic cellular properties of two of them, termed D14 and C22, which reduced the viability in the human pancreatic cancer cells lines MIA PaCa-2, PanC-1 and BxPC-3, but not in the normal pancreatic cell line hTERT-HPNE. Compounds D14 and C22 induced cellular death via apoptosis. D14 and C22 significantly decreased Ras-GTP activity by 33% in MIA PaCa-2 cells. Moreover, D14 decreased AKT phosphorylation by 70% and ERK phosphorylation by 51%, while compound C22 reduced AKT phosphorylation by 60% and ERK phosphorylation by 36%. In addition, compounds C22 and D14 significantly reduced tumor growth by 88.6 and 65.9%, respectively, in a mouse xenograft model. We identified two promising compounds, D14 and C22, that might be useful as therapeutic drugs for pancreatic ductal adenocarcinoma treatment." @default.
• W2908006499 created "2019-01-11" @default.
• W2908006499 creator A5001105973 @default.
• W2908006499 creator A5001750465 @default.
• W2908006499 creator A5007641632 @default.
• W2908006499 creator A5022212872 @default.
• W2908006499 creator A5034604481 @default.
• W2908006499 creator A5041724997 @default.
• W2908006499 creator A5043868058 @default.
• W2908006499 creator A5077100176 @default.
• W2908006499 creator A5078498547 @default.
• W2908006499 creator A5083842021 @default.
• W2908006499 creator A5086030962 @default.
• W2908006499 creator A5088103395 @default.
• W2908006499 creator A5088458670 @default.
• W2908006499 date "2018-12-01" @default.
• W2908006499 modified "2023-10-18" @default.
• W2908006499 title "KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer" @default.
• W2908006499 cites W1968984443 @default.
• W2908006499 cites W1975580333 @default.
• W2908006499 cites W2018159884 @default.
• W2908006499 cites W2035266068 @default.
• W2908006499 cites W2043282329 @default.
• W2908006499 cites W2067174909 @default.
• W2908006499 cites W2067643341 @default.
• W2908006499 cites W2069123478 @default.
• W2908006499 cites W2069537707 @default.
• W2908006499 cites W2079419413 @default.
• W2908006499 cites W2085330118 @default.
• W2908006499 cites W2087523490 @default.
• W2908006499 cites W2091385191 @default.
• W2908006499 cites W2092613403 @default.
• W2908006499 cites W2097358179 @default.
• W2908006499 cites W2105902442 @default.
• W2908006499 cites W2118233996 @default.
• W2908006499 cites W2147993766 @default.
• W2908006499 cites W2157281740 @default.
• W2908006499 cites W2164270482 @default.
• W2908006499 cites W2169961966 @default.
• W2908006499 cites W2219978888 @default.
• W2908006499 cites W2337241649 @default.
• W2908006499 cites W2538983301 @default.
• W2908006499 cites W2603791438 @default.
• W2908006499 doi "https://doi.org/10.1186/s12885-018-5142-7" @default.
• W2908006499 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6310981" @default.
• W2908006499 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30594165" @default.
• W2908006499 hasPublicationYear "2018" @default.
• W2908006499 type Work @default.
• W2908006499 sameAs 2908006499 @default.
• W2908006499 citedByCount "18" @default.
• W2908006499 countsByYear W29080064992019 @default.
• W2908006499 countsByYear W29080064992020 @default.
• W2908006499 countsByYear W29080064992021 @default.
• W2908006499 countsByYear W29080064992022 @default.
• W2908006499 countsByYear W29080064992023 @default.
• W2908006499 crossrefType "journal-article" @default.
• W2908006499 hasAuthorship W2908006499A5001105973 @default.
• W2908006499 hasAuthorship W2908006499A5001750465 @default.
• W2908006499 hasAuthorship W2908006499A5007641632 @default.
• W2908006499 hasAuthorship W2908006499A5022212872 @default.
• W2908006499 hasAuthorship W2908006499A5034604481 @default.
• W2908006499 hasAuthorship W2908006499A5041724997 @default.
• W2908006499 hasAuthorship W2908006499A5043868058 @default.
• W2908006499 hasAuthorship W2908006499A5077100176 @default.
• W2908006499 hasAuthorship W2908006499A5078498547 @default.
• W2908006499 hasAuthorship W2908006499A5083842021 @default.
• W2908006499 hasAuthorship W2908006499A5086030962 @default.
• W2908006499 hasAuthorship W2908006499A5088103395 @default.
• W2908006499 hasAuthorship W2908006499A5088458670 @default.
• W2908006499 hasBestOaLocation W29080064991 @default.
• W2908006499 hasConcept C121608353 @default.
• W2908006499 hasConcept C153911025 @default.
• W2908006499 hasConcept C185592680 @default.
• W2908006499 hasConcept C202751555 @default.
• W2908006499 hasConcept C2780210213 @default.
• W2908006499 hasConcept C502942594 @default.
• W2908006499 hasConcept C54355233 @default.
• W2908006499 hasConcept C553184892 @default.
• W2908006499 hasConcept C55493867 @default.
• W2908006499 hasConcept C86803240 @default.
• W2908006499 hasConcept C95444343 @default.
• W2908006499 hasConcept C96232424 @default.
• W2908006499 hasConceptScore W2908006499C121608353 @default.
• W2908006499 hasConceptScore W2908006499C153911025 @default.
• W2908006499 hasConceptScore W2908006499C185592680 @default.
• W2908006499 hasConceptScore W2908006499C202751555 @default.
• W2908006499 hasConceptScore W2908006499C2780210213 @default.
• W2908006499 hasConceptScore W2908006499C502942594 @default.
• W2908006499 hasConceptScore W2908006499C54355233 @default.
• W2908006499 hasConceptScore W2908006499C553184892 @default.
• W2908006499 hasConceptScore W2908006499C55493867 @default.
• W2908006499 hasConceptScore W2908006499C86803240 @default.
• W2908006499 hasConceptScore W2908006499C95444343 @default.
• W2908006499 hasConceptScore W2908006499C96232424 @default.
• W2908006499 hasIssue "1" @default.
• W2908006499 hasLocation W29080064991 @default.
• W2908006499 hasLocation W29080064992 @default.
• W2908006499 hasLocation W29080064993 @default.
• W2908006499 hasLocation W29080064994 @default.
• W2908006499 hasLocation W29080064995 @default.

• next